All In Biotech

Drug Trial Radar · NCT03715933

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

411

Planned (sponsor's estimate)

Start

Oct 8, 2018

Primary completion

Dec 2028

Study completion Jun 2029

Sponsor

Lead sponsor
Inhibrx Biosciences, IncIndustry
Sponsor type
Industry
First posted
Oct 23, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).

Conditions

  • Ewing Sarcoma
  • Colorectal Adenocarcinoma

Interventions

  • INBRX-109Drug

    Tetravalent DR5 Agonist Antibody

  • IrinotecanDrug

    Chemotherapy

  • TemozolomideDrug

    Chemotherapy

  • carboplatinDrug

    chemotherapy

  • pemetrexedDrug

    chemotherapy

  • LeucovorinDrug

    chemotherapy

  • FluorouracilDrug

    chemotherapy

  • BevacizumabDrug

    targeted therapy

  • Trifluridine + TipiracilDrug

    chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency and severity of adverse events of INBRX-109Time frame: Up to 8 years
  2. Evaluating Tumor Response for colorectal cancers and Ewing sarcomaTime frame: Up to 8 years

Locations

37 sites in 6 countries. Site status is shown where the registry gives one.

  • HonorHealth Research Institute

    Scottsdale, Arizona · Completed

  • Precision NextGen Oncology and Research

    Beverly Hills, California · Recruiting

  • City of Hope

    Duarte, California · Recruiting

  • Valkyrie Clinical Trials

    Los Angeles, California · Recruiting

  • Children's Hospital of Orange County-Rady Children's Health

    Orange, California · Recruiting

  • University of California, San Diego (UCSD) - Moores Cancer Center

    San Diego, California · Withdrawn

  • University of California, San Francisco (UCSF)

    San Francisco, California · Recruiting

  • Sarcoma Oncology Center

    Santa Monica, California · Recruiting

  • University of Colorado Hospital

    Aurora, Colorado · Recruiting

  • Emory University - Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • The University of Chicago

    Chicago, Illinois · Completed

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • START Midwest Michigan, PC

    Grand Rapids, Michigan · Recruiting

  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Completed

  • Oregon Health & Science University

    Portland, Oregon · Recruiting

  • Children's Hospital of Philadelphia- Center for Childhood Cancer Research

    Philadelphia, Pennsylvania · Recruiting

  • University of Pennsylvania Abramson Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • Vanderbilt University School of Medicine

    Nashville, Tennessee · Recruiting

  • UT MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT Oncology

    San Antonio, Texas · Completed

  • University of Virginia

    Charlottesville, Virginia · Recruiting

  • NEXT Oncology - Virginia

    Fairfax, Virginia · Recruiting

  • Centre Leon Berard

    Lyon, France · Recruiting

  • Gustave Roussy

    Villejuif, France · Recruiting

  • La Fondazione e l'Istituto di Candiolo

    Candiolo, Italy · Recruiting

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Italy · Recruiting

  • University Medical Center Groningen

    Groningen, Netherlands · Recruiting

  • Academisch Ziekenhuis Leiden

    Leiden, Netherlands · Recruiting

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain · Recruiting

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain · Recruiting

  • Hospital Clinico San Carlos

    Madrid, Spain · Recruiting

  • Great North Children's Hospital

    London, United Kingdom · Recruiting

  • University College London Hospital

    London, United Kingdom · Recruiting

  • The Royal Marsden NHS Foundation Trust

    London, United Kingdom · Recruiting

  • Royal Manchester Children's Hospital

    Manchester, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.